Vmbook Online ordering

Aryx Therapeutics Inc

Aryx Therapeutics Inc is a public company that specializes in the discovery, development, and commercialization of therapeutics for patients with immune-mediated diseases and rare disorders. The company's lead product candidate is called "AYX2009," which is an oral small molecule inhibitor of the Janus kinase (JAK) 1 enzyme. AYX2009 is currently being evaluated in a Phase 2 clinical trial for the treatment of moderate-to-severe atopic dermatitis, a common inflammatory skin disease.

Aryx Therapeutics is listed on the Nasdaq stock exchange under the ticker symbol "ARYX." As of February 1, 2023, the company has a market capitalization of approximately $265 million, based on a stock price of around $10 per share.

The company was founded in 2016 and is based in Larkspur, California. It is led by a team of experienced executives, including its President and CEO, H. Ward Wolff, who has over 30 years of experience in the biopharmaceutical industry.

Aryx Therapeutics is focused on developing therapies for diseases with significant unmet medical need, including atopic dermatitis, rheumatoid arthritis, and psoriasis. The company has a pipeline of product candidates that target a range of inflammatory diseases and rare disorders. In addition to AYX2009, Aryx Therapeutics is also developing AYX2010, a topical JAK inhibitor for the treatment of mild-to-moderate atopic dermatitis.

Aryx Therapeutics is committed to improving the lives of patients and their families by developing innovative medicines that address meaningful unmet medical needs. The company is well-positioned to continue advancing its pipeline of product candidates and delivering value to its shareholders.